GSM城市站国家站国际

强生22亿美元首付收购Ollin:眼科双抗OLN324纳入管线,黑石另出7.5亿美元资助三期

2026-11-16 · 金融 · GSM News
强生22亿美元首付收购Ollin:眼科双抗OLN324纳入管线,黑石另出7.5亿美元资助三期

强生公司(Johnson & Johnson)11月16日在新泽西州 New Brunswick 宣布,已与 Ollin Biosciences 签署确定性收购协议:强生将先支付22亿美元,后续还可能支付最高约11.25亿美元的监管与商业里程碑付款。Ollin 是一家开发严重眼病疗法的临床阶段生物制药公司。

随收购纳入强生管线的是 OLN324:一款处于三期阶段的在研双特异性抗体,同时靶向视网膜疾病的两条关键通路,血管内皮生长因子(VEGF)与血管生成素-2(Ang2)。该药面向湿性年龄相关性黄斑变性与糖尿病性黄斑水肿等视网膜血管疾病,这两类疾病在全球影响超过4,000万人,是导致视力丧失的主要原因。强生表示,OLN324 具有较高的 Ang2 效力与较小的蛋白形式,有望更好地控制视网膜积液。

强生副总裁、眼科疾病领域负责人 Kip Connor 表示,OLN324 选择性靶向视网膜疾病的两个重要驱动因素,有潜力实现更强、更持久的疾病控制;迄今生成的数据令人信服,显示出可能改变临床面貌的前景,有望更有效地减少视网膜积液、延长给药间隔。

交易还包括一项单独的研发资助安排:黑石生命科学(Blackstone Life Sciences)将在收购交割后分多年向强生支付共7.5亿美元,全额资助 OLN324 的三期临床开发;作为回报,黑石将有资格获得部分监管与销售里程碑付款,以及个位数比例的销售提成。

强生预计交易在2026年年底前完成交割,须获得适用的监管批准并满足惯常交割条件,会计处理将在交割时或之前公布。据 Ollin 今年6月的官方发布,该公司当时完成3.3亿美元 B 轮融资,OLN324 在164人参加的头对头概念验证研究中与法瑞西单抗(faricimab)相比显示出更快、更明显的视网膜解剖学改善,全球三期试验原定2026年下半年启动。

关联:强生双抗组合一期结果:晚期前列腺癌患者73% PSA降幅过半,近半数降幅逾90%

(来源:强生公司)

Johnson & Johnson to Acquire Ollin for $2.2 Billion Upfront, Adding Phase 3 Eye Antibody OLN324; Blackstone to Fund Development With $750 Million

Johnson & Johnson announced in New Brunswick, New Jersey, on November 16 that it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapies for serious eye diseases, for $2.2 billion upfront, with the potential for additional regulatory and commercial milestone payments of up to approximately $1.125 billion.

The acquisition would add OLN324 to Johnson & Johnson's pipeline, a Phase 3 investigational bispecific antibody designed to target two key pathways in retinal diseases, vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2). OLN324 is being developed for retinal vascular diseases including wet age-related macular degeneration and diabetic macular edema, which together affect more than 40 million people worldwide and are leading causes of vision loss. Johnson & Johnson said OLN324 is a next-generation antibody with high Ang2 potency and a small protein format that could enable improved control of retinal fluid.

"OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control," said Kip Connor, Vice President and Ophthalmology Disease Area Stronghold Leader at Johnson & Johnson, adding that the data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments.

Under a separate development funding agreement, Blackstone Life Sciences will pay a total of $750 million to Johnson & Johnson over multiple years to fully fund the Phase 3 development of OLN324, contingent upon the acquisition closing. In return, Blackstone will be eligible to receive certain regulatory and sales milestone payments as well as single-digit royalties.

Johnson & Johnson expects the transaction to close before the end of 2026, subject to applicable regulatory approvals and customary closing conditions, and said the accounting treatment will be communicated on or before the close. According to Ollin's own June announcement, the company had closed a $330 million Series B financing, and OLN324 had shown faster and greater retinal drying than faricimab in a 164-patient head-to-head proof-of-concept study, with global Phase 3 trials planned to start in the second half of 2026.

Related: Johnson & Johnson Phase 1 results: pasritamig plus JNJ-9401 posts 73% PSA response rate in advanced prostate cancer

(Source: Johnson & Johnson)

来源:强生公司

发布:GSM·美国(发布链接)

图片来源:图:强生公司位于新泽西州 New Brunswick 的总部入口标识。ajay_suresh 摄,CC BY 4.0,经 Wikimedia Commons。 / Photo: Entrance sign at Johnson & Johnson headquarters in New Brunswick, New Jersey. By ajay_suresh, CC BY 4.0, via Wikimedia Commons.

GSM Global · 本篇英文版 English edition of this story

本频道最新更多 ›

← 返回金融 全部新闻 关于我们

GSM首页白宫联邦加州南加各州社会军事司法选举世界中国城市站国家站移民宣传专题视频直播放映厅电子书电子报科技金融教育医疗影视音乐体育文旅时尚演出活动娱乐游戏生活美食户外交通汽车地产保险儿童长者留学生宠物信仰非盈利机构